Figure 4
Percent change in modeled Ktrans of anterior and posterior brain RG-2 gliomas as a result of the 15 minute intravenous infusion of normal saline or respective bradykinin B2 agonist. (A) Anterior brain RG-2 gliomas; NS (N = 6), BK (N = 8), Lys-BK (N = 8), Met-Lys-BK (N = 7), Labradimil (N = 13); (B) Posterior brain RG-2 gliomas; NS (N = 6), BK (N = 8), Lys-BK (N = 8), Met-Lys-BK (N = 7), Labradimil (N = 12). P-values reported are adjusted values using Dunnett-Hsu adjustments for multiple post hoc comparisons of treatment effect.